| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 06/05/2024 | 13:14 | Edgar (US Regulatory) | Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] | NASDAQ:BLRX | BioLineRx Ltd |
| 17/04/2024 | 13:00 | PR Newswire (US) | BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting | NASDAQ:BLRX | BioLineRx Ltd |
| 08/01/2024 | 06:15 | Edgar (US Regulatory) | Form EFFECT - Notice of Effectiveness | NASDAQ:BLRX | BioLineRx Ltd |
| 29/12/2023 | 22:20 | Edgar (US Regulatory) | Form S-8 - Securities to be offered to employees in employee benefit plans | NASDAQ:BLRX | BioLineRx Ltd |
| 29/12/2023 | 22:15 | Edgar (US Regulatory) | Form F-3 - Registration statement by foreign private issuers | NASDAQ:BLRX | BioLineRx Ltd |
| 20/11/2023 | 12:25 | IH Market News | Monday’s Wall Street Highlights: GM, Microsoft, Citigroup, Amazon, and more | NASDAQ:BLRX | BioLineRx Ltd |
| 01/11/2023 | 12:43 | PR Newswire (Canada) | BioLineRx a conclu un accord de licence exclusive pour le motixafortide en Asie, sous les conseils de MSQ Ventures | NASDAQ:BLRX | BioLineRx Ltd |
| 31/10/2023 | 14:00 | PR Newswire (US) | BioLineRx entered Exclusive License Agreement to Motixafortide in Asia, advisored by M.S.Q. Ventures | NASDAQ:BLRX | BioLineRx Ltd |
| 26/10/2023 | 20:18 | Edgar (US Regulatory) | Form SC 13D - General statement of acquisition of beneficial ownership | NASDAQ:BLRX | BioLineRx Ltd |
| 18/10/2023 | 23:07 | AllPennyStocks.com | New Collaboration Could Revolutionize Treatment of Chronic Spinal Cord Injuries | NASDAQ:BLRX | BioLineRx Ltd |
| 11/09/2023 | 13:00 | PR Newswire (US) | BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma | NASDAQ:BLRX | BioLineRx Ltd |
| 30/08/2023 | 13:16 | IH Market News | Wednesday’s Wall Street Highlights: Ambarella, Alphabet, Toyota, HP Inc, Vinfast, and more | NASDAQ:BLRX | BioLineRx Ltd |
| 23/06/2023 | 22:17 | Edgar (US Regulatory) | Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k) | NASDAQ:BLRX | BioLineRx Ltd |
| 22/03/2023 | 12:48 | Edgar (US Regulatory) | Annual and Transition Report (foreign Private Issuer) (20-f) | NASDAQ:BLRX | BioLineRx Ltd |
| 20/01/2023 | 22:32 | Edgar (US Regulatory) | Securities Registration: Employee Benefit Plan (s-8) | NASDAQ:BLRX | BioLineRx Ltd |
| 15/11/2022 | 18:05 | TipRanks | Bioline RX Ltd Sponsored ADR (BLRX) Receives a Buy from H.C. Wainwright | NASDAQ:BLRX | BioLineRx Ltd |
| 04/11/2022 | 21:30 | PR Newswire (US) | BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification | NASDAQ:BLRX | BioLineRx Ltd |
| 28/09/2022 | 18:15 | TipRanks | Bioline RX Ltd Sponsored ADR (BLRX) Gets a Buy from H.C. Wainwright | NASDAQ:BLRX | BioLineRx Ltd |
| 20/09/2022 | 22:31 | Edgar (US Regulatory) | Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) | NASDAQ:BLRX | BioLineRx Ltd |
| 19/09/2022 | 16:53 | TipRanks | BioLineRx (NASDAQ:BLRX) Nosedives on $15M Direct Offering | NASDAQ:BLRX | BioLineRx Ltd |
| 09/09/2022 | 22:16 | Edgar (US Regulatory) | Amended Annual and Transition Report (foreign Private Issuer) (20-f/a) | NASDAQ:BLRX | BioLineRx Ltd |
| 30/06/2022 | 15:42 | PR Newswire (Canada) | BioLineRx conclut une entente de codéveloppement avec GenFleet pour développer davantage le Motixafortide pour le traitement de l'adénocarcinome canalaire pancréatique, selon les conseils de MSQ Ventures | NASDAQ:BLRX | BioLineRx Ltd |
| 29/06/2022 | 14:00 | PR Newswire (Canada) | BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures | NASDAQ:BLRX | BioLineRx Ltd |
| 16/03/2022 | 16:15 | TipRanks | H.C. Wainwright Thinks Biolinerx’s Stock is Going to Recover | NASDAQ:BLRX | BioLineRx Ltd |
| 11/02/2022 | 12:50 | Edgar (US Regulatory) | Amended Statement of Ownership (sc 13g/a) | NASDAQ:BLRX | BioLineRx Ltd |
| 18/01/2022 | 17:40 | TipRanks | Biolinerx (BLRX) Receives a Buy from H.C. Wainwright | NASDAQ:BLRX | BioLineRx Ltd |
| 21/09/2021 | 18:13 | Edgar (US Regulatory) | Confidential Treatment Order (ct Order) | NASDAQ:BLRX | BioLineRx Ltd |
| 25/02/2021 | 12:05 | Edgar (US Regulatory) | Notice of Effectiveness (effect) | NASDAQ:BLRX | BioLineRx Ltd |
| 23/02/2021 | 15:13 | Edgar (US Regulatory) | Post-effective Amendment to Registration Statement (pos Am) | NASDAQ:BLRX | BioLineRx Ltd |
| 28/01/2021 | 17:31 | TipRanks | These 2 Penny Stocks Could Rally All the Way to $11, Say Analysts | NASDAQ:BLRX | BioLineRx Ltd |